Shanghai Haohai Biological Technology Co., Ltd. (HAOHAI BIOTEC) disclosed a share buy-back on 20 July 2026, repurchasing 161,000 H shares on the Hong Kong Stock Exchange for a total consideration of HKD 2.64 million. The transaction price ranged between HKD 16.14 and HKD 16.85 per share, implying a volume-weighted average cost of approximately HKD 16.40 per share.

The repurchased shares represent 0.0716% of the company’s 224.98 million issued ordinary shares (excluding treasury shares) and 0.46% of the 3.48 million-share limit authorised by shareholders at the 29 May 2026 annual general meeting. All 161,000 shares are intended for cancellation and remain outstanding as at the disclosure date.

Post-transaction, the company’s issued share capital is unchanged at 34.78 million H shares and 190.20 million A shares, alongside 3.85 million A-share treasury shares. Upon completion of cancellation procedures, the total issued share count will decline accordingly.

Under Hong Kong Listing Rules, HAOHAI BIOTEC is subject to a moratorium on new share issues or treasury share disposals until 19 August 2026.